Hyperkalemia: How High Potassium Is Recognized and Why It Matters
What causes high potassium, its symptoms, why kidney disease and ACE inhibitors raise it, and when hyperkalemia becomes a medical emergency.
Health & Evidence Library
Evidence on kidney function, electrolytes, digestive symptoms, liver health, anemia, clotting, and connected diagnostic decisions.
36 guides · Page 1 of 1
What causes high potassium, its symptoms, why kidney disease and ACE inhibitors raise it, and when hyperkalemia becomes a medical emergency.
Home care for hemorrhoids and anal fissures, how to tell them apart, and the rectal bleeding red flags that mean you should get checked.
Evidence-based heartburn relief: which self-care steps and medicines work, how antacids, H2 blockers, and PPIs differ, and when to get checked.
Most gallstones cause no symptoms and are left alone. Learn which ones need surgery, what a gallbladder attack feels like, and the red flags.
A food allergy is an immune reaction that can be dangerous; an intolerance is non-immune. How to tell them apart and test wisely.
How to relieve chronic constipation: start with fiber and fluids, step up to an osmotic then a stimulant laxative, and know the alarm signs that need care.
ANNEXA-I found better hematoma control with andexanet than usual care but more thrombosis. Learn what the trial did, what it did not prove, and the US update.
A urine albumin-to-creatinine ratio can reveal kidney damage before eGFR falls. Learn the A1, A2, and A3 categories and why repeat testing matters.
Trials support selective care without antibiotics for some immunocompetent adults with mild uncomplicated diverticulitis, not for every patient.
Why WHO, gastroenterology, kidney, and heart-failure guidance use different ferritin cutoffs, and why context and transferrin saturation matter.
How clinicians confirm thrombocytopenia, distinguish immune thrombocytopenia from urgent alternatives, and interpret bleeding risk and treatment evidence.
When inherited and acquired clotting tests can change care, when they add little, and why clot context and assay timing matter.
The gut and liver exchange nutrients, bile acids, microbial products, and immune signals. The gut-liver axis explains the route, not a single disease.
How resmetirom became the first FDA-approved MASH treatment, what its biopsy endpoints showed, and what accelerated approval still requires.
How the 4Ts score estimates pretest probability of HIT from platelet fall, timing, thrombosis, and alternative causes, and how it guides laboratory testing.
DAPA-CKD and EMPA-KIDNEY changed kidney care. This guide explains composite outcomes, eGFR slope, eligibility, benefits, and harms.
What FIB-4 can and cannot tell you about liver scarring, how it feeds the AASLD noninvasive pathway, and where the score misleads.
Why proton pump inhibitors should be stopped when the indication ends, not because a study linked them to harm, and how to read that evidence.
Baveno VII rules clinically significant portal hypertension in or out from liver stiffness and platelet count, without a catheter pressure reading.
Why liver societies replaced NAFLD and NASH with MASLD and MASH in 2023, what the MetALD category adds, and how to appraise a disease renaming.
Fluid has broad guideline backing but a weak grade; thiazides, citrate, and allopurinol help mainly in urine-defined subgroups.
Why JAK2 V617F and exon 12 mutations carry such weight in the WHO criteria for polycythemia vera, and what a negative test still leaves open.
Why a stool protein called fecal calprotectin, the cutoff behind it, and a patient's baseline risk decide who can skip colonoscopy when separating IBD from IBS.
A practical guide to ALT, AST, alkaline phosphatase, and bilirubin, and how the R ratio sorts an abnormal panel into hepatocellular or cholestatic.
Why ferritin, transferrin saturation, and MCV are read together, and how inflammation can hide real iron deficiency behind a normal-looking ferritin.
A close read of the ASH 2020 sickle cell guidelines and how their two labels, strength and certainty, sort screening, transfusion, and hydroxyurea advice.
How the ACG 2022 guideline uses a PPI trial, endoscopy, and pH testing to confirm, or overturn, a GERD diagnosis.
How the 2023 U.S. atrial fibrillation guideline shifted from a single CHA2DS2-VASc cutoff to an annual-risk threshold and several validated scores.
Why tTG-IgA plus a total IgA comes first, why gluten must stay in the diet during testing, and when guidelines allow diagnosis without a biopsy.
Why hepatitis C is now curable, what "cure" (SVR12) really measures, and the reasoning behind screening every adult aged 18 to 79.
How HBeAg, HBsAg, ALT, and HBV DNA stage chronic hepatitis B, and why AASLD treats some phases with antivirals while monitoring others.
How the 2024 ACG guideline reshaped H. pylori care, why bismuth quadruple therapy is now first line, and why a test of cure is required.
What FIDELIO-DKD, FIGARO-DKD, and the pooled FIDELITY analysis show about finerenone's kidney and heart benefits, and its hyperkalemia trade-off.
Why creatinine and cystatin C eGFR values differ, what KDIGO 2024 advises, and how to read the mortality signal when they diverge.
How guideline panels weigh DOACs against warfarin, when bridging heparin still helps, and why drug interactions keep warfarin in play for some patients.
Why multiplying a patient's age by 10 to set the D-dimer threshold safely rules out pulmonary embolism in older adults, and where the rule stops.